Autolus Therapeutics plc business relationships
Companies named in Autolus Therapeutics plc’s 10-K filed 2026-03-27, and public companies whose annual reports name Autolus Therapeutics plc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Autolus Therapeutics plc’s annual report 11
“We have collaboration and license agreements with, for example, BioNTech SE, Cabaletta Bio Inc., Moderna Inc., Bristol-Myers Squibb Company, and others.” SEC filing
“(i) Strategic Collaboration and Financing Agreement, (the "Blackstone Collaboration Agreement");” SEC filing
“We filed a resale registration statement on Form S-3 to register the ADSs we sold to BioNTech in 2024.” SEC filing
“Except for the Moderna Milestone, the Company did not recognize any variable consideration with regards to the development milestones and sales-based milestones with its customers for the year ended December 31, 2025 and 2024, as they are deemed not probable.” SEC filing
“The royalty will be increased if BioNTech, its affiliates or sublicensees commercialize a Binder Licensed Product in an indication and country in which we or our affiliates or licensees also commercialize a product containing the same binders.” SEC filing
“Under the License Agreement, BioNTech has also agreed to financially support the expansion of the clinical development program and planned commercialization of obe-cel.” SEC filing
“Research, Option and License Agreement with Moderna” SEC filing
“• our plans to collaborate, or statements regarding our current collaborations with BioNTech SE ("BioNTech") and others;” SEC filing
“AUCATZYL is manufactured at our dedicated commercial manufacturing site, the Nucleus, in Stevenage, U.K. We intend for the Nucleus to meet the global supply demands of AUCATZYL, with Cardinal Health 105, LLC serving as our commercial distribution partner in the US.” SEC filing
“We have collaboration and license agreements with, for example, BioNTech SE, Cabaletta Bio Inc., Moderna Inc., Bristol-Myers Squibb Company, and others.” SEC filing
“Amendment 2 to Supply Agreement, dated as of September 27, 2023, by and between Autolus Limited and Miltenyi Biotec B.V. & Co. KG.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.